Dupilumab Significantly Improves Sleep Outcomes In Adult Patients With Atopic Dermatitis: Results From Five Randomized Clinical Trials

Sleep disturbances are part of a symptom triad, along with itch and pain, that patients with atopic dermatitis (AD) report as being frequent and burdensome. The effects of dupilumab on sleep were evaluated in adults with chronic AD in 5 randomized, double-blind, placebo-controlled clinical trials (N=2632). The phase 2b (NCT01859988) and the two phase 3 SOLO trials (SOLO 1, NCT02277743; SOLO 2, NCT02277769) were 16-week studies of dupilumab monotherapy, the 16-week CAFÉ (NCT02755649) and the 52-week CHRONOS trials (NCT02260986) evaluated dupilumab with concomitant topical corticosteroids (TCS).